A number of other brokerages have also recently commented on EPZM. HC Wainwright set a $25.00 price target on Epizyme and gave the stock a “buy” rating in a research note on Monday, June 24th. Wedbush reaffirmed an “outperform” rating and issued a $21.00 price target on shares of Epizyme in a research note on Wednesday, June 12th. Zacks Investment Research cut Epizyme from a “buy” rating to a “hold” rating and set a $15.00 price target on the stock. in a research note on Wednesday, August 14th. Finally, BidaskClub cut Epizyme from a “hold” rating to a “sell” rating in a research note on Tuesday, September 24th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $17.25.
Epizyme stock traded up $0.10 during trading hours on Wednesday, reaching $10.88. The company had a trading volume of 421,671 shares, compared to its average volume of 829,968. The company has a debt-to-equity ratio of 0.03, a current ratio of 10.56 and a quick ratio of 10.56. The company has a 50-day moving average price of $12.17 and a 200 day moving average price of $12.65. The firm has a market cap of $981.38 million, a price-to-earnings ratio of -6.33 and a beta of 2.37. Epizyme has a 12-month low of $5.14 and a 12-month high of $16.59.
Several institutional investors and hedge funds have recently bought and sold shares of EPZM. Aperio Group LLC purchased a new position in shares of Epizyme during the second quarter valued at approximately $72,000. Rockefeller Capital Management L.P. purchased a new position in shares of Epizyme during the second quarter valued at approximately $88,000. United Services Automobile Association purchased a new position in shares of Epizyme during the second quarter valued at approximately $134,000. BP PLC purchased a new position in shares of Epizyme during the second quarter valued at approximately $177,000. Finally, HarbourVest Partners LLC purchased a new position in shares of Epizyme during the second quarter valued at approximately $177,000. 86.30% of the stock is currently owned by hedge funds and other institutional investors.
Epizyme Company Profile
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Further Reading: G-20
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.